What is Azilsartan Kemedoxomil used for ?

Edarbi (azilsartan medoxomil), a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist.

The drug substance used in the drug product formulation is the potassium salt of azilsartan medoxomil, also known by the US accepted name of azilsartan kamedoxomil and is chemically described as (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2\’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate monopotassium salt.

Its empirical formula is C30H23KN4O8.

Indications:

It is an angiotensin II receptor blocker( ARB) indicated for the treatment of hypertension to lower blood pressure.

Lowering blood pressure reduces the threat of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive medicines from a wide variety of pharmacologic classes, including the class to which this Medicine basically belongs.

There are no controlled trials demonstrating threat reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular threat operation, including, as applicable, lipid control, diabetes operation, antithrombotic remedy, smoking conclusion, exercise, and limited sodium input. numerous cases will bear further than one medicine to achieve blood pressure Pretensions.

Numerous multitudinous antihypertensive medicines, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that its blood pressure reduction, and not some other pharmacologic property of the medicines, that\’s largely responsible for those benefits.

The largest and most harmonious cardiovascular outgrowth benefit has been a reduction in the threat of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular threat, and the absolute threat increase per mmHg is lesser at advanced blood pressures so indeed modest reductions of severe hypertension can give a substantial benefit.

Relative threat reduction from blood pressure reduction is Analogous across populations with varying absolute threat, so the absolute benefit is lesser in cases who are at advanced threat independent of their hypertension( for illustration, cases with diabetes or hyperlipidemia), and similar cases would be anticipated to profit from more aggressive treatment to a lower blood pressure thing. Some antihypertensive medicines have lower blood pressure goods( as monotherapy) in black cases, and numerous antihypertensive medicines have fresh approved suggestions and goods(e.g., on angina, heart failure, or diabetic order complaint).

These considerations may guide the selection of remedies. Edarbi may be used alone or in combination with other antihypertensive agents.